If you have been reading about thymus extract and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
| Property | Value | Notes |
|---|---|---|
| 化学分类 | 线性肽 | 由28个氨基酸组成 |
| 分子量 | 约3108 Da | 合成版本一致 |
| 外观 | 白色至类白色粉末 | 冻干品 |
| 溶解度 | 易溶于水 | 微溶于有机溶剂 |
| 储存温度 | -20°C（冻干） | 溶解后2-8°C |
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Tranexamic acid is a medication used to treat or prevent excessive blood loss from major trauma, postpartum bleeding, surgery, tooth removal, nosebleeds, and heavy menstruation. It is also used for hereditary angioedema. It is taken either by mouth, injection into a vein, or by intramuscular injection. Tranexamic acid is a synthetic analog of the amino acid lysine. It serves as an antifibrinolytic by reversibly binding four to five lysine receptor sites on plasminogen. This decreases the conversion of plasminogen to plasmin, preventing fibrin degradation and preserving the framework of fibrin's matrix structure. Tranexamic acid has roughly eight times the antifibrinolytic activity of an older analogue, ε-aminocaproic acid. Tranexamic acid also directly inhibits the activity of plasmin with weak potency (IC50 = 87 mM), and it can block the active-site of urokinase plasminogen activator (uPA) with high specificity (Ki = 2 mM), one of the highest among all the serine proteases. Side effects are rare; they include changes in color vision, seizures, blood clots, and allergic reactions. Tranexamic acid appears to be safe for use during pregnancy and breastfeeding. Tranexamic acid was first made in 1962 by Japanese researchers Shosuke and Utako Okamoto. It is on the World Health Organization's List of Essential Medicines. Tranexamic acid is available as a generic drug.
"UNODC - Bulletin on Narcotics: The narcotic pepper - The chemistry and pharmacology of Piper methysticum and related species". United Nations Office on Drugs and Crime. 1973. pp. Issue 2. Retrieved 19 February 2014. Kava ban documents Piper methysticum information from the Hawaiian Ecosystems at Risk project (HEAR) "Kava" . Encyclopædia Britannica. Vol. 14 (9th ed.). 1882.
==== Dosage and safety margin ==== The data sheets for meloxicam products for cats also state that: "Meloxicam has a narrow therapeutic safety margin in cats and clinical signs of overdose may be seen at relatively small overdose levels."
27 March – Humza Yousaf is elected as the Leader of the Scottish National Party and subsequently, First Minister of Scotland. He is the youngest holder of the position in history at just 37 years of age upon entry to office, the first from an ethnic minority background, the first Muslim to hold the office and the first First Minister with facial hair. 28 March Humza Yousaf is confirmed as Scotland's First Minister by a vote in the Scottish Parliament. Kate Forbes is to leave the Scottish Government after turning down a position in the Yousaf ministry. 29 March – Humza Yousaf is sworn in as Scotland's First Minister at Edinburgh's Court of Session and begins naming his Cabinet. 30 March The Parliamentary Standards Committee recommends that former Scottish National Party MP Margaret Ferrier be suspended from the House of Commons for 30 days for breaching COVID-19 regulations in September 2020 when she took a train home from London following a positive COVID test. Humza Yousaf attends his first session of First Minister's Questions since his election as First Minister. The session is interrupted on several occasions by climate change protestors, forcing the Presiding Officer of the Scottish Parliament to clear the gallery of visitors.
== Other uses == C4, a variation of Command and control, meaning "Command, Control, Communications and Computers" C4, the monogram of Christian IV of Denmark, used in the city arms of Kristianstad, Sweden since 1622 C4 Extreme, a sports nutrition supplement product line by Cellucor, which includes C4 energy drinks
Sources: en.wikipedia.org
was arrested in Dubai on 18 June 2020, due to an international arrest warrant that was sent out by the Belgian courts for his involvement in large scale drug trafficking, but he was eventually released on bail. The majority of the Turtle clan members are currently suspected of hiding out in Dubai and Nador, Morocco. In 2016, a member of the family celebrated his wedding in the Borgerhout district of Antwerp, causing controversy throughout the country as well as on social media. The controversy revolved particularly around the procession that included dozens of luxury cars, which paraded through the lower class district of Borgerhout. According to the Belgian press, the price of these cars was estimated at €7 million. Since 2018, many grenade attacks have occurred in the streets of Antwerp. They are particularly linked to the organisation of the Turtles.
=== Artificial === De novo designed peptides which self-assemble in the presence of copper (Cu), forming supramolecular assemblies were presented by Korendovych et al. Additionally there are examples of metallopeptides that are, at least partially, composed of non-natural amino acids with possible applications in drug discovery and biomaterials.
== See also == Fetal fibronectin Fibronectin type I domain Fibronectin type II domain Fibronectin type III domain Monobody, an engineered antibody mimetic based on the structure of the fibronectin type III domain Substrate adhesion molecules
=== Everton === On 20 July 2021, Townsend signed for fellow English club Everton on a two-year contract upon the expiry of his contract with Crystal Palace. Townsend made his debut on 14 August 2021, assisting Richarlison's goal as Everton came from behind to beat Southampton 3–1 on the opening day of the season. On 24 August 2021, Townsend scored the winning goal in an EFL Cup round two fixture against Huddersfield Town. On 13 September 2021, Townsend scored his first Premier League goal for Everton, smashing in a long-range effort from 30 yards to put Everton ahead as they went on to beat Burnley 3–1; this goal won him the Premier League Goal of the Month award. On 20 March 2022, Townsend was forced off the pitch in the 16th minute of an eventual 4–0 loss against former club Crystal Palace in the quarter-finals of the FA Cup, and was later revealed to have suffered an anterior cruciate ligament injury. Subsequently, he went on to miss the remainder of the 2021–22 season as well as the entirety of the 2022–23 season, after which he departed Everton at the conclusion of his contract, having not played in over 18 months.
Sources: en.wikipedia.org
它不是经典的内分泌激素，而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现，而非经血液循环作用于远隔器官。
天然胸腺素α1主要从胸腺组织提取，也可在脾脏和淋巴结中检出。目前研究和临床使用的多为化学合成版本，不再依赖动物组织。
胸腺素组分5是牛胸腺提取物的粗组分，包含多种肽。胸腺素α1是其中一种被纯化和表征的单一肽，具有明确的28个氨基酸序列。
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.